The commentary on design and endpoints of clinical trials in hepatocellular carcinoma
(HCC) by Llovet et al.(1) gives a relevant contribution to the methodological improvement of …

Highlights•Most common types of drug-induced liver injuries in oncology are presented.•
Hepatotoxicity of chemotherapy and molecular targeted therapies is reviewed.•Imaging …

Background. Patients with advanced or metastatic cancer treated in Phase I clinical trials are
considered to have a poor prognosis. Survival from first treatment in a Phase I trial was …

Background Chemotherapy is increasingly used before hepatic resection, with controversial
impact regarding liver function. This study aimed to assess the capacity of 99mTc-labelled …

4581 Background: ABT-869 is a novel orally active, potent and selective inhibitor of the
vascular endothelial growth factor and platelet derived growth factor families of receptor …

In the context of sequential treatments, time-to-event outcomes such as PFS are proposed to
have great clinical utility owing to the fact that PFS better captures timing of transition to …

The article offers information on the recommendations over inclusion of organ-impaired
patients in oncology trials. Topics discussed include challenges of identifying investigators …

Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that
occurs either as a predictable event when an individual is exposed to toxic doses of some …

Introduction/Methods A discussion forum was hosted by the German not-for-profit
Association for Applied Human Pharmacology (AGAH eV) to critically review key eligibility …

To promptly identify and evaluate liver safety events, an evidence-based liver safety system
was created for global Phase I–III clinical trials. The goals of this system included improving …